CFO4Life Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

CFO4Life Group’s Portfolio BCLI Stock Details BCLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-800	Closed	-$40K	–	147
2022 Q1	$40K	Hold	800	–	–	0.01%	155
2021 Q4	$48K	Hold	800	–	–	0.01%	154
2021 Q3	$40K	Hold	800	–	–	0.01%	141
2021 Q2	$46K	Hold	800	–	–	0.01%	140
2021 Q1	$46K	Hold	800	–	–	0.01%	144
2020 Q4	$54K	Hold	800	–	–	0.02%	140
2020 Q3	$203K	Hold	800	–	–	0.07%	121
2020 Q2	$135K	Hold	800	–	–	0.05%	122
2020 Q1	$56K	Hold	800	–	–	0.03%	112
2019 Q4	$51K	Buy	+800	New	+$46.4K	0.02%	127

Other funds holding BCLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AHB

Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WCG

Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CFO4Life Group's BCLI Position: Q2 2022 in Review

CFO4Life Group sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2022, closing a stake of 800 shares — an estimated $40K sold.

CFO4Life Group first reported a position in BCLI in Q4 2019 and held it in 10 quarters. The position peaked at $203K in Q3 2020. 48 funds tracked by Wall St. Rank hold BCLI as of Q2 2022.

CFO4Life Group reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2022 after selling out during the quarter.
CFO4Life Group sold 800 BRAINSTORM CELL THERAPUTC shares in Q2 2022, an estimated $40K.
CFO4Life Group first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2019 and held it in 10 quarters.
CFO4Life Group's BRAINSTORM CELL THERAPUTC position peaked at $203K in Q3 2020.
48 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2022.

Based on CFO4Life Group's 13F filing for Q2 2022, filed 20 Jul 2022.